Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
Serena Ferrari, Marianna Cannoletta, Matteo Generali, Lucia Cazzato, Angelo CagnacciDepartment of Obstetrics, Gynecology, and Pediatrics, Azienda Ospedaliero, Universitaria di Modena, ItalyAbstract: Since their introduction in 1959, development of hormonal contraceptives has been ongoing, with the u...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-09-01
|
Series: | Open Access Journal of Contraception |
Online Access: | http://www.dovepress.com/efficacy-safety-and-patient-acceptability-of-the-combined-chlormadinon-a5199 |
id |
doaj-63acb38e68f044a3be7275e69e83ea0f |
---|---|
record_format |
Article |
spelling |
doaj-63acb38e68f044a3be7275e69e83ea0f2020-11-24T23:21:51ZengDove Medical PressOpen Access Journal of Contraception1179-15272010-09-012010default93101Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptiveSerena FerrariMarianna Cannoletta, Matteo Generaliet al.Serena Ferrari, Marianna Cannoletta, Matteo Generali, Lucia Cazzato, Angelo CagnacciDepartment of Obstetrics, Gynecology, and Pediatrics, Azienda Ospedaliero, Universitaria di Modena, ItalyAbstract: Since their introduction in 1959, development of hormonal contraceptives has been ongoing, with the ultimate aim of creating not only an effective and safe contraceptive method, but also a drug able to meet the need for treatment of other conditions, such as acne, seborrhea, and hirsutism, with few or no side effects. With this objective, a new progestin, chlormadinone acetate (CMA), has been developed as a derivative of progesterone for ­contraception. This new molecule has been introduced in combination with ethinylestradiol (EE) 30 µg as a safe ­contraceptive with antiandrogenic properties. Many clinical studies have investigated this new oral combination and found it to be safe, with a Pearl Index similar to that of other combined hormonal contraceptives. CMA, because of its antiandrogenic properties, has been also considered effective for resolution of acne, seborrhea, and hirsutism. The data show it to be a safe molecule in terms of glucose and lipid metabolism. No major weight changes have been linked with its use, and it seems to be the only progestin able to reduce fat mass during use. The CMA-EE combination is well tolerated and acceptable to women. Adverse events related to its use are similar to those reported with other third-generation ­contraceptives. We can conclude that CMA-EE is an effective, safe, and well tolerated ­antiandrogenic hormonal contraceptive.Keywords: chlormadinone acetate, acne, weight, metabolism, safety, hormonal contraceptive http://www.dovepress.com/efficacy-safety-and-patient-acceptability-of-the-combined-chlormadinon-a5199 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Serena Ferrari Marianna Cannoletta, Matteo Generali et al. |
spellingShingle |
Serena Ferrari Marianna Cannoletta, Matteo Generali et al. Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive Open Access Journal of Contraception |
author_facet |
Serena Ferrari Marianna Cannoletta, Matteo Generali et al. |
author_sort |
Serena Ferrari |
title |
Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive |
title_short |
Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive |
title_full |
Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive |
title_fullStr |
Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive |
title_full_unstemmed |
Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive |
title_sort |
efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive |
publisher |
Dove Medical Press |
series |
Open Access Journal of Contraception |
issn |
1179-1527 |
publishDate |
2010-09-01 |
description |
Serena Ferrari, Marianna Cannoletta, Matteo Generali, Lucia Cazzato, Angelo CagnacciDepartment of Obstetrics, Gynecology, and Pediatrics, Azienda Ospedaliero, Universitaria di Modena, ItalyAbstract: Since their introduction in 1959, development of hormonal contraceptives has been ongoing, with the ultimate aim of creating not only an effective and safe contraceptive method, but also a drug able to meet the need for treatment of other conditions, such as acne, seborrhea, and hirsutism, with few or no side effects. With this objective, a new progestin, chlormadinone acetate (CMA), has been developed as a derivative of progesterone for ­contraception. This new molecule has been introduced in combination with ethinylestradiol (EE) 30 µg as a safe ­contraceptive with antiandrogenic properties. Many clinical studies have investigated this new oral combination and found it to be safe, with a Pearl Index similar to that of other combined hormonal contraceptives. CMA, because of its antiandrogenic properties, has been also considered effective for resolution of acne, seborrhea, and hirsutism. The data show it to be a safe molecule in terms of glucose and lipid metabolism. No major weight changes have been linked with its use, and it seems to be the only progestin able to reduce fat mass during use. The CMA-EE combination is well tolerated and acceptable to women. Adverse events related to its use are similar to those reported with other third-generation ­contraceptives. We can conclude that CMA-EE is an effective, safe, and well tolerated ­antiandrogenic hormonal contraceptive.Keywords: chlormadinone acetate, acne, weight, metabolism, safety, hormonal contraceptive |
url |
http://www.dovepress.com/efficacy-safety-and-patient-acceptability-of-the-combined-chlormadinon-a5199 |
work_keys_str_mv |
AT serenaferrari efficacysafetyandpatientacceptabilityofthecombinedchlormadinoneacetateethinylestradioloralcontraceptive AT mariannacannolettaampnbspmatteogenerali efficacysafetyandpatientacceptabilityofthecombinedchlormadinoneacetateethinylestradioloralcontraceptive AT etal efficacysafetyandpatientacceptabilityofthecombinedchlormadinoneacetateethinylestradioloralcontraceptive |
_version_ |
1725569838604091392 |